dc.contributor.author
Llorens Torres, Franc
dc.contributor.author
Villar Piqué, Anna
dc.contributor.author
Hermann, Peter
dc.contributor.author
Schmitz, Matthias
dc.contributor.author
Calero, Olga
dc.contributor.author
Stehmann, Christiane
dc.contributor.author
Sarros, Shannon
dc.contributor.author
Moda, Fabio
dc.contributor.author
Ferrer, Isidro (Ferrer Abizanda)
dc.contributor.author
Poleggi, Anna
dc.contributor.author
Pocchiari, Maurizio
dc.contributor.author
Catania, Marcella
dc.contributor.author
Klotz, Sigrid
dc.contributor.author
O'Regan, Carl
dc.contributor.author
Brett, Francesca
dc.contributor.author
Heffernan, Josephine
dc.contributor.author
Ladogana, Anna
dc.contributor.author
Collins, Steven J.
dc.contributor.author
Calero, Miguel
dc.contributor.author
Kovacs, Gabor G.
dc.contributor.author
Zerr, Inga
dc.date.issued
2021-01-20T12:12:32Z
dc.date.issued
2021-01-20T12:12:32Z
dc.date.issued
2020-02-12
dc.date.issued
2021-01-20T12:12:32Z
dc.identifier
https://hdl.handle.net/2445/173289
dc.description.abstract
Human prion diseases are classified into sporadic, genetic, and acquired forms. Within this last group, iatrogenic Creutzfeldt-Jakob disease (iCJD) is caused by human-to-human transmission through surgical and medical procedures. After reaching an incidence peak in the 1990s, it is believed that the iCJD historical period is probably coming to an end, thanks to lessons learnt from past infection sources that promoted new prion prevention and decontamination protocols. At this point, we sought to characterise the biomarker profile of iCJD and compare it to that of sporadic CJD (sCJD) for determining the value of available diagnostic tools in promptly recognising iCJD cases. To that end, we collected 23 iCJD samples from seven national CJD surveillance centres and analysed the electroencephalogram and neuroimaging data together with a panel of seven CSF biomarkers: 14-3-3, total tau, phosphorylated/total tau ratio, alpha-synuclein, neurofilament light, YKL-40, and real-time quaking induced conversion of prion protein. Using the cut-off values established for sCJD, we found the sensitivities of these biomarkers for iCJD to be similar to those described for sCJD. Given the limited relevant information on this issue to date, the present study validates the use of current sCJD biomarkers for the diagnosis of future iCJD cases.
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/biom10020290
dc.relation
Biomolecules, 2020, vol. 10, num. 2
dc.relation
https://doi.org/10.3390/biom10020290
dc.rights
cc-by (c) Llorens Torres, Franc et al., 2020
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Malaltia de Creutzfeldt-Jakob
dc.subject
Marcadors bioquímics
dc.subject
Creutzfeldt-Jakob disease
dc.subject
Biochemical markers
dc.title
Diagnostic accuracy of prion disease biomarkers in iatrogenic Creutzfeldt-Jakob disease
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion